Today, we take a look at clinical-stage biopharma firm Gossamer Bio, whose stock is up some 175% so far in 2025. Seralutinib, Gossamer's lead asset, is advancing to late-stage development and has ...
Hosted on MSN
Gossamer Bio Reports Q2 2025 Financial Results
Gossamer Bio ( (GOSS)) has released its Q2 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...
For Investors and Media: Bryan Giraudo, Chief Financial Officer & Chief Operating Officer Gossamer Bio Investor Relations [email protected] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback